Cabaletta Bio, Inc. (CABA) Stock

Cabaletta Bio, Inc. (CABA) is a Healthcare stock trading at $2.85 (as of 2026-06-18), with a market capitalization of $616.35M and a trailing P/E of -1.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company developing engineered T cell therapies for B cell–driven autoimmune conditions. Its CAAR T cell platforms are designed to recognize and remove specific B cells, with product candidates including DSG3-CAART for mucosal pemphigus vulgaris and Hemophilia A and additional programs in myasthenia gravis and other pemphigus subtypes.

Valuation — source: SEC EDGAR (first-party)
Price$2.85
Market Cap$616.35M
P/E Ratio-1.7
EV / EBITDA-2.1
Price / Book4.75
Price / Sales87.33
DCF Value (model)$-19.49
DCF Upside vs Price-783.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$6.03M
Net Margin-2783.2%
Return on Equity-169.8%
Current Ratio2.95
Revenue Growth (YoY)-39.8%
EPS Growth (YoY)-10.3%
FCF Growth (YoY)46.3%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.56 (distress)
Valuation vs Sector & Industry
Stock P/E-1.7
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-108.1%
vs Industry-109.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderT. Rowe Price Investment Management, Inc. ($29.81M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSteven A. Nichtberger
Employees161
CountryUS
IPO Date2019-10-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Voyager Therapeutics, Inc. (VYGR)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Shattuck Labs, Inc. (STTK)
  • Armata Pharmaceuticals, Inc. (ARMP)
  • Prelude Therapeutics Incorporated (PRLD)
  • Surrozen, Inc. (SRZN)
  • Milestone Pharmaceuticals Inc. (MIST)
  • ProQR Therapeutics N.V. (PRQR)
CABA earnings history · CABA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.